Skip to main content

Table 1 Demographic data of patient cohort and validation cohort.

From: Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors

 

Patient cohort

Validation cohort

Age [median (range)]

59 (19–82)

61 (9–84)

Sex

  

Male

55

37

Female

36

26

Location

  

Frontal

18

20

Temporal

19

18

Parietal

23

13

Occipital

1

3

>1 lobe

30

9

Grade

  

II

18

11

III

8

7

IV

65

45

Events

  

Death

65 (follow-up: 6–104 months, median 17 months)

41 (follow-up: 2–39 months, median 12 months)

Censored

26 (follow-up: 8–48 months, median 13 months)

22 (follow-up: 16–52 months, median 16.5 months)

Surgery

  

Partial

55

24

Complete

36

39

Radiotherapy

  

Yes

72a

57a

No

19

6

Chemotherapy

  

Yes

23b

43

No

35

6

Information not available

33

14

  1. Data are n unless otherwise stated.
  2. aPostoperative radiotherapy (a total dose of 60 Gy in 30–33 fractions).
  3. bGliadel in 4 cases, Temodal in 14 cases and Gliadel plus Temodal in 5 cases.